Répertoire du corps professoral

Roles of the tumor suppressor PALB2 at the intersection of DNA repair and synthetic lethal strategies in cancer
Programme: Subvention Projet
Organisme(s) subventionnaire(s): Instituts de recherche en santé du Canada
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 octobre 2024 au 30 septembre 2029

Unveiling the roles of Poly(ADP)ribose Glycohydrolase (PARG) in DNA repair and cancer
Programme: Subvention de fonctionnement
Organisme(s) subventionnaire(s): Société de recherche sur le cancer
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 septembre 2024 au 31 août 2026

Characterization of novel breast cancer susceptibility genes through large-scale targeted sequencing and functional assays.
Programme: Subvention Projet
Organisme(s) subventionnaire(s): Instituts de recherche en santé du Canada
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 avril 2024 au 31 mars 2029

Emerging roles of Zinc Finger PAR-Interacting Proteins (ZIPPs) in DNA double-strand break (DSB) repair: implications in PARPi therapy
Programme: Subvention Projet
Organisme(s) subventionnaire(s): Instituts de recherche en santé du Canada
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 avril 2024 au 31 mars 2029

Caractérisation de nouveaux gènes de susceptibilité au cancer du sein
Programme: Programme de soutien aux organismes de recherche et d’innovation (PSO) - International
Organisme(s) subventionnaire(s): Ministère de l'Économie et de l'Innovation et de l'énergie, Fondation du CHU de Québec
Type de financement: Subvention
Établissement tête: Université Laval
Du 15 février 2024 au 31 mars 2027

Réseau de recherche sur le cancer (RRCancer)
Programme: ONCOPOLE EMC2: Équipes multi-institutionnelles contre le cancer
Organisme(s) subventionnaire(s): Fonds de recherche du Québec - Santé
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 avril 2023 au 31 mars 2026

Tumor biobanking was supported by the Banque de tissus et de données en cancers solides of the Réseau de recherche sur le cancer (RRCancer)...The RRCancer is funded by the Oncopole...de l'Économie, de l'Innovation et de l'Énergie du Québec.
Programme: ONCOPOLE EMC2: Équipes multi-institutionnelles contre le cancer
Organisme(s) subventionnaire(s): Fonds de recherche du Québec - Santé
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 avril 2023 au 31 mars 2025

Canada Research Chair in DNA repair and Cancer Therapeutics
Programme: Chaires de recherche du Canada - Fonctionnement
Organisme(s) subventionnaire(s): Instituts de recherche en santé du Canada
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 juillet 2020 au 30 juin 2027

Decoding the DNA double-strand break repair pathways: from mechanistic insights to human genome instability diseases
Programme: Subventions Fondation
Organisme(s) subventionnaire(s): Instituts de recherche en santé du Canada
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 juillet 2018 au 30 juin 2025

Personalized Risk Assesment for Prevention and Early Detection of Breast Cancer : Integration and Implementation (PERSPECTIVE II)
Programme: Projets de recherche appliquée à grande échelle - Large-Scale Applied Research Project
Organisme(s) subventionnaire(s): Regroupement de compagnies et corporations canadiennes, Fondation du CHU de Québec, Génome Québec, Ministère de la santé (Ontario), Ministère de l'Économie, de la Science et de l'Innovation, Instituts de recherche en santé du Canada, Fondation du cancer du sein du Québec, Génome Canada
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 novembre 2017 au 30 septembre 2025

Fonds de cancérologie et ses fonds liés
Organisme(s) subventionnaire(s): Fondation de l'Université Laval
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 avril 2005 au 30 avril 2029

Financements des 2 dernières années

Grand prix scientifique
Programme: Prix d'excellence - Grand prix scientifique
Organisme(s) subventionnaire(s): Fondation du cancer du sein du Québec
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 avril 2022 au 31 mars 2023

The contribution of RAD51C and RAD51D to breast and ovarian cancer
Programme: Subvention de recherche
Organisme(s) subventionnaire(s): National Institute of Health (USA)
Type de financement: Subvention
Établissement tête: Mayo Clinic Rochester
Du 1 mai 2021 au 30 avril 2023

Infrastructure for a Tier I CRC in DNA repair and cancer therapeutics
Programme: Fonds des leaders John-R.-Evans - CRC (anciennement : Chaires de recherche du Canada - infrastructure et Fonds des leaders - Volet 2)
Organisme(s) subventionnaire(s): Fondation Canadienne pour l'innovation (La), Ministère de la Santé et des Services sociaux
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 juillet 2020 au 31 décembre 2022

Patient stratification based on DNA repair functionality for cancer precision medicine
Programme: Subvention d'équipe: ERA-Net PerMed
Organisme(s) subventionnaire(s): Fonds de recherche du Québec - Santé, Instituts de recherche en santé du Canada
Type de financement: Subvention
Établissement tête: Vall d'Hebron University Hospital
Du 1 janvier 2020 au 31 décembre 2022

Poly(ADP-ribose) writers, readers, and erasers: Functions in DNA double-strand break repair and synthetic lethality
Programme: Subvention Projet
Organisme(s) subventionnaire(s): Instituts de recherche en santé du Canada
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 octobre 2019 au 30 septembre 2024

Characterization of HR-Killer1 and identification of small molecules for cancer therapy and enhanced gene editing using CRISPR/Cas9-based DNA repair strategies
Programme: Subvention Projet
Organisme(s) subventionnaire(s): Instituts de recherche en santé du Canada
Type de financement: Subvention
Établissement tête: Dalhousie University
Du 1 avril 2018 au 31 mars 2023

Investigating the Role of RECQL in Breast Cancer Susceptibility
Programme: Subvention Projet
Organisme(s) subventionnaire(s): Instituts de recherche en santé du Canada
Type de financement: Subvention
Établissement tête: University of Toronto
Du 1 avril 2017 au 31 mars 2024

Encadrements terminés dans les 5 dernières années

Daryl Hyacinth Acuna Ronato, Doctorat en biologie cellulaire et moléculaire

Yuandi Gao, Maîtrise en biologie cellulaire et moléculaire - avec mémoire

Yuandi Gao, Doctorat en biologie cellulaire et moléculaire

Julia O'Sullivan, Doctorat en biologie cellulaire et moléculaire

Louis Marie Paul Michel Nonfoux, Maîtrise en médecine moléculaire - avec mémoire

Thibaut Peterlini, Doctorat en biologie cellulaire et moléculaire

Publications des 5 dernières années

RAD51 protects against nonconservative DNA double-strand break repair through a nonenzymatic function. Nucleic acids research, 2022/03/21. DOI 10.1093/nar/gkac073

A DNA repair-independent role for alkyladenine DNA glycosylase in alkylation-induced unfolded protein response. Proceedings of the National Academy of Sciences of the United States of America, 2022/03/01. DOI 10.1073/pnas.2111404119

A functionally impaired missense variant identified in French Canadian families implicates FANCI as a candidate ovarian cancer-predisposing gene. Genome medicine, 2021/12/03. DOI 10.1186/s13073-021-00998-5

FAN1 exo- not endo-nuclease pausing on disease-associated slipped-DNA repeats: A mechanism of repeat instability. Cell reports, 2021/12/01. DOI 10.1016/j.celrep.2021.110078

Cockayne syndrome group B protein regulates fork restart, fork progression and MRE11-dependent fork degradation in BRCA1/2-deficient cells. Nucleic acids research, 2021/12/01. DOI 10.1093/nar/gkab1173

Starvation-induced proteasome assemblies in the nucleus link amino acid supply to apoptosis. Nature communications, 2021/11/30. DOI 10.1038/s41467-021-27306-4

Functions of the CSB Protein at Topoisomerase 2 Inhibitors-Induced DNA Lesions. Frontiers in cell and developmental biology, 2021/10/22. DOI 10.3389/fcell.2021.727836

Molecular Determinant of DIDS Analogs Targeting RAD51 Activity. Molecules (Basel, Switzerland), 2021/09/08. DOI 10.3390/molecules26185460

XAB2 promotes Ku eviction from single-ended DNA double-strand breaks independently of the ATM kinase. Nucleic acids research, 2021/09/01. DOI 10.1093/nar/gkab785

ZNF768 links oncogenic RAS to cellular senescence. Nature communications, 2021/08/17. DOI 10.1038/s41467-021-24932-w

Personalized Risk Assessment for Prevention and Early Detection of Breast Cancer: Integration and Implementation (PERSPECTIVE I&I). Journal of personalized medicine, 2021/06/04. DOI 10.3390/jpm11060511

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging. Journal of visualized experiments : JoVE, 2021/04/28. DOI 10.3791/62553

Addressing the dark matter of gene therapy: technical and ethical barriers to clinical application. Human genetics, 2021/04/08. DOI 10.1007/s00439-021-02272-5

Synergistic effects of type I PRMT and PARP inhibitors against non-small cell lung cancer cells. Clinical epigenetics, 2021/03/10. DOI 10.1186/s13148-021-01037-1

Zinc finger protein E4F1 cooperates with PARP-1 and BRG1 to promote DNA double-strand break repair. Proceedings of the National Academy of Sciences of the United States of America, 2021/03/01. DOI 10.1073/pnas.2019408118

Animal models of Fanconi anemia: A developmental and therapeutic perspective on a multifaceted disease. Seminars in cell & developmental biology, 2021/02/06. DOI 10.1016/j.semcdb.2020.11.010

SUMOylation mediates CtIP's functions in DNA end resection and replication fork protection. Nucleic acids research, 2021/01/01. DOI 10.1093/nar/gkaa1232

MRE11-RAD50-NBS1 Complex Is Sufficient to Promote Transcription by RNA Polymerase II at Double-Strand Breaks by Melting DNA Ends. Cell reports, 2021/01/01. DOI 10.1016/j.celrep.2020.108565

FAN1, a DNA Repair Nuclease, as a Modifier of Repeat Expansion Disorders. Journal of Huntington's disease, 2021/01/01. DOI 10.3233/jhd-200448

Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy. Journal of translational medicine, 2020/11/19. DOI 10.1186/s12967-020-02613-4

PALB2 Variants: Protein Domains and Cancer Susceptibility. Trends in cancer, 2020/11/01. DOI 10.1016/j.trecan.2020.10.002

DDX5 resolves R-loops at DNA double-strand breaks to promote DNA repair and avoid chromosomal deletions. NAR cancer, 2020/09/25. DOI 10.1093/narcan/zcaa028

Genome-wide R-loop analysis defines unique roles for DDX5, XRN2, and PRMT5 in DNA/RNA hybrid resolution. Life science alliance, 2020/08/03. DOI 10.26508/lsa.202000762

Limiting the DNA Double-Strand Break Resectosome for Genome Protection. Trends in biochemical sciences, 2020/06/06. DOI 10.1016/j.tibs.2020.05.003

Missense PALB2 germline variant disrupts nuclear localization of PALB2 in a patient with breast cancer. Familial cancer, 2020/04/01. DOI 10.1007/s10689-020-00163-8

Variants of uncertain clinical significance in hereditary breast and ovarian cancer genes: best practices in functional analysis for clinical annotation. Journal of medical genetics, 2020/03/09. DOI 10.1136/jmedgenet-2019-106368

A slipped-CAG DNA-binding small molecule induces trinucleotide-repeat contractions in vivo. Nature genetics, 2020/02/14. DOI 10.1038/s41588-019-0575-8

The Canadian Rare Diseases Models and Mechanisms (RDMM) Network: Connecting Understudied Genes to Model Organisms. American journal of human genetics, 2020/02/01. DOI 10.1016/j.ajhg.2020.01.009

Functional analysis of genetic variants in the high-risk breast cancer susceptibility gene PALB2. Nature communications, 2019/11/22. DOI 10.1038/s41467-019-13194-2

CSB interacts with BRCA1 in late S/G2 to promote MRN- and CtIP-mediated DNA end resection. Nucleic acids research, 2019/11/01. DOI 10.1093/nar/gkz784

A global functional analysis of missense mutations reveals two major hotspots in the PALB2 tumor suppressor. Nucleic acids research, 2019/11/01. DOI 10.1093/nar/gkz780

Functional characterization of 84 PALB2 variants of uncertain significance. Genetics in medicine : official journal of the American College of Medical Genetics, 2019/10/21. DOI 10.1038/s41436-019-0682-z

Interactions of the Rad51 inhibitor DIDS with human and bovine serum albumins: Optical spectroscopy and isothermal calorimetry approaches. Biochimie, 2019/09/25. DOI 10.1016/j.biochi.2019.09.016

MRE11-RAD50-NBS1 promotes Fanconi Anemia R-loop suppression at transcription-replication conflicts. Nature communications, 2019/09/19. DOI 10.1038/s41467-019-12271-w

A Fanci knockout mouse model reveals common and distinct functions for FANCI and FANCD2. Nucleic acids research, 2019/08/01. DOI 10.1093/nar/gkz514

Poly(ADP-ribose) polymerase-1 antagonizes DNA resection at double-strand breaks. Nature communications, 2019/07/04. DOI 10.1038/s41467-019-10741-9

Arginine methylation of the DDX5 helicase RGG/RG motif by PRMT5 regulates resolution of RNA:DNA hybrids. The EMBO journal, 2019/06/21. DOI 10.15252/embj.2018100986

SAM68 interaction with U1A modulates U1 snRNP recruitment and regulates mTor pre-mRNA splicing. Nucleic acids research, 2019/05/01. DOI 10.1093/nar/gkz099

Novel RNA and DNA strand exchange activity of the PALB2 DNA binding domain and its critical role for DNA repair in cells. eLife, 2019/04/29. DOI 10.7554/elife.44063

Emerging roles of eraser enzymes in the dynamic control of protein ADP-ribosylation. Nature communications, 2019/03/12. DOI 10.1038/s41467-019-08859-x

BRN2 suppresses apoptosis, reprograms DNA damage repair, and is associated with a high somatic mutation burden in melanoma. Genes & development, 2019/02/25. DOI 10.1101/gad.314633.118

Perturbing cohesin dynamics drives MRE11 nuclease-dependent replication fork slowing. Nucleic acids research, 2019/02/01. DOI 10.1093/nar/gky519

PRMT7 methylates eukaryotic translation initiation factor 2α and regulates its role in stress granule formation. Molecular biology of the cell, 2019/01/30. DOI 10.1091/mbc.e18-05-0330

The Tumor Suppressor PALB2: Inside Out. Trends in biochemical sciences, 2019/01/10. DOI 10.1016/j.tibs.2018.10.008